Stifel Financial
CRBP icon

Stifel Financial’s Corbus Pharmaceuticals CRBP Stock Holding History

Stifel Financial’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,577
Closed -$18K – 3305
2022
Q3 		$18K Buy
3,577
+724
+25% +$5.11K ﹤0.01% 3238
2022
Q2 		$22K Buy
2,853
+1,438
+102% +$13.9K ﹤0.01% 3270
2022
Q1 		$23K Buy
1,415
+602
+74% +$7.98K ﹤0.01% 3336
2021
Q4 		$15K Buy
813
+45
+6% +$1.22K ﹤0.01% 3349
2021
Q3 		$23K Buy
768
+345
+82% +$13.6K ﹤0.01% 3302
2021
Q2 		$23K Buy
423
+2
+0.5% +$111 ﹤0.01% 3292
2021
Q1 		$25K Sell
421
-337
-44% -$22.2K ﹤0.01% 3188
2020
Q4 		$28K Sell
758
-771
-50% -$28.8K ﹤0.01% 3013
2020
Q3 		$83K Buy
1,529
+778
+104% +$141K ﹤0.01% 2775
2020
Q2 		$189K Sell
751
-59
-7% -$11.9K ﹤0.01% 2599
2020
Q1 		$128K Buy
+810
New +$137K ﹤0.01% 2542

Other funds holding CRBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stifel Financial's CRBP Position: Q4 2022 in Review

Stifel Financial sold out of Corbus Pharmaceuticals (CRBP) in Q4 2022, closing a stake of 3,577 shares — an estimated $18K sold.

Stifel Financial first reported a position in CRBP in Q1 2020 and held it in 11 quarters. The position peaked at $189K in Q2 2020. 63 funds tracked by Wall St. Rank hold CRBP as of Q4 2022.

  • Stifel Financial reported no remaining Corbus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Stifel Financial sold 3,577 Corbus Pharmaceuticals shares in Q4 2022, an estimated $18K.
  • Stifel Financial first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 11 quarters.
  • Stifel Financial's Corbus Pharmaceuticals position peaked at $189K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2022.

Based on Stifel Financial's 13F filing for Q4 2022, filed 13 Feb 2023.